News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,337 Results
Type
Article (42021)
Company Profile (435)
Press Release (665881)
Section
Business (208605)
Career Advice (2020)
Deals (35991)
Drug Delivery (102)
Drug Development (83472)
Employer Resources (170)
FDA (16383)
Job Trends (15070)
News (352488)
Policy (33019)
Tag
Academia (2626)
Alliances (50843)
Alzheimer's disease (1360)
Approvals (16355)
Artificial intelligence (215)
Bankruptcy (367)
Best Places to Work (11841)
Biotechnology (329)
Breast cancer (231)
Cancer (1759)
Cardiovascular disease (138)
Career advice (1683)
CAR-T (127)
Cell therapy (374)
Clinical research (67032)
Collaboration (697)
Compensation (375)
COVID-19 (2623)
C-suite (167)
Data (1656)
Diabetes (216)
Diagnostics (6342)
Earnings (86673)
Employer resources (147)
Events (114380)
Executive appointments (578)
FDA (17302)
Funding (633)
Gene therapy (266)
GLP-1 (686)
Government (4444)
Healthcare (19098)
Infectious disease (2736)
Inflammatory bowel disease (127)
Interviews (310)
IPO (16740)
Job creations (3699)
Job search strategy (1433)
Layoffs (466)
Legal (7962)
Lung cancer (260)
Manufacturing (244)
Medical device (13412)
Medtech (13417)
Mergers & acquisitions (19618)
Metabolic disorders (580)
Neuroscience (1792)
NextGen: Class of 2025 (6752)
Non-profit (4545)
Northern California (2118)
Obesity (325)
Opinion (212)
Patents (164)
People (58209)
Phase I (21055)
Phase II (29595)
Phase III (21858)
Pipeline (728)
Postmarket research (2600)
Preclinical (8968)
Radiopharmaceuticals (257)
Rare diseases (343)
Real estate (6005)
Regulatory (22377)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1826)
Startups (3753)
United States (18958)
Vaccines (630)
Weight loss (227)
Date
Today (18)
Last 7 days (609)
Last 30 days (2664)
Last 365 days (35500)
2025 (4560)
2024 (36301)
2023 (41016)
2022 (52277)
2021 (56763)
2020 (54921)
2019 (47421)
2018 (35699)
2017 (33029)
2016 (32349)
2015 (38400)
2014 (32187)
2013 (27112)
2012 (29222)
2011 (29867)
2010 (27995)
Location
Africa (735)
Arizona (219)
Asia (38918)
Australia (6479)
California (4885)
Canada (1725)
China (403)
Colorado (221)
Connecticut (242)
Europe (84965)
Florida (692)
Georgia (165)
Illinois (471)
Indiana (262)
Maryland (759)
Massachusetts (3757)
Michigan (200)
Minnesota (340)
New Jersey (1374)
New York (1379)
North Carolina (897)
Northern California (2118)
Ohio (175)
Pennsylvania (1112)
South America (1108)
Southern California (1826)
Texas (717)
Utah (145)
Washington State (485)
708,337 Results for "curie therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic
The biotech incubator said Wednesday the majority of the fund will be for clinical proof-of-concept studies, bringing the total funds raised by Curie.Bio to nearly $1 billion.
June 26, 2024
·
1 min read
·
Kate Goodwin
Genetown
Curie.Bio Raises $380M Pro Rata Series A Fund To Support Portfolio Companies Through Clinical Trials
We’re excited to announce today that we have closed $380 million for our latest fund, bringing the total funds raised by Curie.Bio to nearly $1 billion.
June 26, 2024
·
4 min read
Genetown
Curis to Present at Upcoming Healthcare Conferences in April
Curis, Inc. today announced that James Dentzer , President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024.
April 4, 2024
·
1 min read
Press Releases
Curis Announces Additional Data from TakeAim Leukemia Study
December 11, 2024
·
7 min read
Genetown
Curis to Present Updated Data from the TakeAim Leukemia Study
Curis, Inc. announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET.
May 10, 2024
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Genetown
Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, announced updated data from the ongoing TakeAim Leukemia study in relapsed/refractory AML to be presented at the ASCO and EHA conferences.
May 14, 2024
·
9 min read
Business
Curis Provides First Quarter 2024 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.
May 7, 2024
·
11 min read
Deals
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)-April 5, 2024
Curis, Inc. today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares.
April 5, 2024
·
2 min read
Business
Curis Provides Fourth Quarter 2023 Business Update
Curis, Inc. reported its business update and financial results for the quarter ended December 31, 2023.
February 8, 2024
·
12 min read
1 of 70,834
Next
